Institute: Centre for Human Drug Research, Netherlands
Biography
lngrid de Visser - Kamerling graduated in Medical Biology from Leiden University. She obtained her PhD from Leiden University in 2003 and became a registered clinical pharmacologist in 2005. From 2004 to 2007, she worked as policy coordinator in the research department of the Dutch Heart Foundation.Currently, she is Associate Director in clinical trials, and her main research focus is on general infectious
diseases with main focus on respiratory viruses and controlled human infection models.
Key Publications
1. Prins ML, van der Plas JL, Vissers MF, Berends CL, Tresch G, Soergel M, Fernández E, van den Berge N, Duijsings D, Zitt C, Stavropoulou V. Viral clearance, pharmacokinetics and tolerability of ensovibep in patients with mild to moderate COVID‐19: A phase 2a, open‐label, single‐dose escalation study. British Journal of Clinical Pharmacology. 2023 Mar;89(3):1105-14.
2. Van der Plas JL, van Esdonk MJ, Kamerling IM, Cohen AF. Accelerating vaccine trial conduct in a pandemic with a hot spot‐based inclusion strategy using trial and epidemic simulation. Clinical and Translational Science. 2021 Nov;14(6):2391-8.
3. Kuiper VP, Rosendaal FR, Kamerling IM, Visser LG, Roestenberg M. Assessment of risks associated with severe acute respiratory syndrome coronavirus 2 experimental human infection studies. Clinical Infectious Diseases. 2021 Sep 1;73(5):e1228-34.
4. Verdijk P, van der Plas JL, van Brummelen EM, Jeeninga RE, de Haan CA, Roestenberg M, Burggraaf J, Kamerling IM. First-in-human administration of a live-attenuated RSV vaccine lacking the G-protein assessing safety, tolerability, shedding and immunogenicity: a randomized controlled trial. Vaccine. 2020 Sep 3;38(39):6088-95.
5. Van der Plas JL, Roestenberg M, Cohen AF, Kamerling IM. How to expedite early‐phase SARS‐CoV‐2 vaccine trials in pandemic setting—a practical perspective. British Journal of Clinical Pharmacology. 2021 May;87(5):2167.
6. Van Der Plas JL, Verdijk P, Van Brummelen EM, Jeeninga RE, Roestenberg M, Burggraaf J, Kamerling IM. Prevalent levels of RSV serum neutralizing antibodies in healthy adults outside the RSV-season. Human Vaccines & Immunotherapeutics. 2020 Jun 2;16(6):1322-6.
Web Links of Interest